Company: ARTL
Filing Date: 2025-09-30
Form Type: 424B5
Source: 0001640334-25-001747
Chunk: 1

Company: ARTELO BIOSCIENCES, INC.
Filing Date: 2025-09-30
Form: 424B5
Chunk 1
---
 this prospectus supplement, we have sold all $451,527 of Common Stock that was available for sale under the ATM Prospectus, and accordingly, no further shares may be offered or sold under the ATM Prospectus unless and until we file another prospectus supplement.

The purpose of this prospectus supplement is to update the ATM Prospectus to reflect the ATM Offering Size Reduction, suspend sales under the Sales Agreement, and to clarify that no further shares may be offered or sold under the ATM Prospectus unless and until we file another prospectus supplement. Except as modified by this prospectus supplement, the terms of the ATM offering remain unchanged, and the Sales Agreement remains in full force and effect.

The aggregate market value of our outstanding shares of Common Stock held by non-affiliates as of September 29, 2025, is $18,399,248, based on 1,555,493 shares of Common Stock outstanding, of which 1,551,370 are held by non-affiliates, and a closing price on Nasdaq of $11.86 on July 31, 2025, which is within 60 days of the date of this prospectus supplement. We are providing this information in accordance with General Instruction I.B.6. of Form S-3. However, as described elsewhere in this prospectus supplement, we have sold all $451,527 of Common Stock that was available for sale under the ATM Prospectus, as supplemented hereby, and as a result, no further shares may be offered or sold under this prospectus supplement unless and until we file another prospectus supplement.

Investing in our shares of Common Stock involves a high degree of risk and uncertainty. See “Risk Factors” beginning on page S-9 of the ATM Prospectus and the other documents that are incorporated by reference in the ATM Prospectus and the accompanying base prospectus.

NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR PASSED UPON THE ADEQUACY OR ACCURACY OF THIS PROSPECTUS SUPPLEMENT, THE PRIOR PROSPECTUS SUPPLEMENTS OR THE ACCOMPANYING PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

<div align='center'>R.F. Lafferty & Co., Inc.

______________

The date of this prospectus supplement is September 30, 2025.</div>